<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fluvastatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01095</strong>&#160; (APRD00346)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (<span class="caps">HMG</span>-CoA) reductase. <span class="caps">HMG</span>-CoA reductase catalyzes the conversion of <span class="caps">HMG</span>-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic <span class="caps">HMG</span>-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01095/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01095/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01095.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01095.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01095.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01095.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01095.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01095">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fluvastatin Sodium </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000088/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000088/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: ZGGHKIMDNBDHJB-UHFFFAOYNA-M</li>
              <li>Monoisotopic Mass: 433.166531173</li>
              <li>Average Mass: 433.4478</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000088">DBSALT000088</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Canef</td><td>AstraZeneca</td></tr><tr><td>Cranoc</td><td>Astellas</td></tr><tr><td>Lescol</td><td>Novartis Pharmaceuticals </td></tr><tr><td>Lescol XL</td><td>Novartis Pharmaceuticals</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hydroxymethylglutaryl-coa-reductase-inhibitors">Hydroxymethylglutaryl-CoA Reductase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>93957-54-1</td></tr><tr><th>Weight</th><td>Average: 411.4659<br>Monoisotopic: 411.18458653</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>26</sub>FNO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>FJLGEFLZQAZZCD-NDDZYTDBNA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/s2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)N1C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C2=CC=CC=C12)C1=CC=C(F)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyrroles</td></tr><tr><th>Subclass</th><td>Substituted Pyrroles</td></tr><tr><th>Direct parent</th><td>Phenylpyrroles</td></tr><tr><th>Alternative parents</th><td>Indoles; Beta Hydroxy Acids and Derivatives; Fluorobenzenes; Heterocyclic Fatty Acids; Unsaturated Fatty Acids; N-substituted Pyrroles; Aryl Fluorides; Secondary Alcohols; Carboxylic Acids; Enolates; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>indole; indole or derivative; beta-hydroxy acid; fluorobenzene; hydroxy acid; aryl halide; benzene; n-substituted pyrrole; aryl fluoride; secondary alcohol; enolate; polyamine; carboxylic acid derivative; carboxylic acid; organofluoride; amine; alcohol; organonitrogen compound; organohalogen</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>To be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia. </td></tr><tr><th>Pharmacodynamics</th><td>Fluvastatin, the first synthetically-derived HMG-CoA reductase inhibitor, is a hydrophilic, acidic, antilipemic agent used to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb), to slow the progression of coronary atherosclerosis in patients with CHD and as secondary prevention therapy in patients with CHD to reduce the risk of requiring coronary revascularization procedures. Although similar to lovastatin, simvastatin, and pravastatin, fluvastatin has a shorter half-life, no active metabolites, extensive protein binding, and minimal CSF penetration. Fluvastatin acts primarily in the liver. It is prepared as a racemate of two erythro enantiomers of which the 3R,5S enantiomer exerts the pharmacologic effect. </td></tr><tr><th>Mechanism of action</th><td>Fluvastatin selectively and competitively inhibits the hepatic enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. Inhibition results in a decrease in hepatic cholesterol levels which stimulates the synthesis of LDL receptors and increases hepatic uptake of LDL cholesterol. The end result is decreased levels of plasma total and LDL cholesterol. </td></tr><tr><th>Absorption</th><td>Rapidly and almost completely absorbed (&gt; 90%), but undergoes extensive first pass metabolism. Bioavailability is 24% (range 9-50%) when a 10 mg dose is given. The mean relative bioavailability of the extended-release tablet is 29% (range: 9% to 66%) compared to an immediate-release capsule administered under fasting conditions. When given orally, fluvastatin reaches peak concentrations (Tmax) in less than one hour.  Taking the extended release tablet with a high-fat meal will delay absorption (Tmax = 6 hours) and increase bioavailability by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after a high fat meal is less than the peak concentration following a single dose or twice daily dose of the 40 mg fluvastatin capsule.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.35 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>98% bound to plasma proteins. At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Undergoes hepatic metabolism primarily via hydroxylation of the indole ring at the 5- and 6-positions to 5-hydroxy fluvastatin and 6-hydroxy fluvastatin, respectively. N-dealkylation to N-desisopropyl fluvastatin and beta-oxidation of the side chain also occurs. Metabolized primarily by the CYP2C9 isozyme system (75%), and to a lesser extent by CYP3A4 (~20%) and CYP2C8 (~5%). Hydroxylated metabolites retain some pharmcological activity, but are present as conjugates (glucuronides and sulfates) in the blood and are rapidly eliminated via bile into feces. Both enantiomers of fluvastatin are metabolized in a similar manner. Fluvastatin also undergoes glucuronidation via UGT enzymes. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Fluvastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00213">6-Hydroxyfluvastatin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/214">Details</a></td></tr><tr><td>Fluvastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00214">N-Deisopropyl-fluvastatin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/215">Details</a></td></tr><tr><td>Fluvastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00215">5-Hydroxyfluvastatin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/216">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>When orally administered, fluvastatin is primarily excreted in the faces ( ~90%) as metabolites, with less than 2% present as unchanged drug. Approximately 5% was recovered in the urine. </td></tr><tr><th>Half life</th><td>3 hours </td></tr><tr><th>Clearance</th><td><ul>
	<li>0.8 L/h/kg</li>
	<li>107 &#177; 38.1 L/h [Hypercholesterolemia patients receiving a single dose of 20 mg]</li>
	<li>87.8 &#177; 45 L/h [Hypercholesterolemia patients receiving 20 mg twice daily]</li>
	<li>108 &#177; 44.7 L/h [Hypercholesterolemia patients receiving 40 mg single]</li>
	<li>64.2 &#177; 21.1 L/h [Hypercholesterolemia patients receiving 40 mg twice daily]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Generally well-tolerated. May cause gastrointestinal upset (diarrhea, nausea, constipation, gas, abdominal pain), myotoxicity (mypothy, myositis, rhabdomyolysis), and hepatotoxicity.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Fluvastatin Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9943</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5053</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5176</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7395</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8381</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8823</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7305</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6111</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6003</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.675</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8983</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6314</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8811</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.809</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7909
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9472 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9899
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.848
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>20 mg, 40 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>80 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Fluvastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if fluvastatin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Fluvastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if fluvastatin if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>Increased/decreased effect according to spacing</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased risk of rhabdomyolysis with this combination</td></tr><tr><td><a href="/drugs/DB00375">Colestipol</a></td><td>Increased/decreased effect according to spacing</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Fluvastatin may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if fluvastatin if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Fluvastatin via metabolism decrease. OATP transporter protein inhibition.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Fluvastatin, when administered concomitantly with etravirin, may experience an increase in serum concentration. It is recommended to monitor for signs of toxicity from fluvastatin, such as myopathy and hepatic enzyme elevations.</td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>Inhibitors of CYP3A4 and P-glycoprotein may increase serum concentrations of repaglinide. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Fluvastatin may increase the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if fluvastatin is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>May be taken with or without food, but should be taken consistently.</li>
<li>When given with an evening meal, Cmax and AUC decreased while Tmax increased 2-fold</li></ul></td></tr></tbody></table>